ESMO open · 2026
Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sternschuss M, Whiting K, Arbuiso A, Gupta A, Bent E, Alvarez N, Regazzi A, Liang S, Ahmed F, Akin O, Beylergil V, Niglio S, Lage D, Funt S A, Bajorin D, Iyer G, Aggen D, Ostrovnaya I, Rosenberg J E
Аннотация
BACKGROUND: Platinum-based chemotherapy (PBC) is frequently used after first-line enfortumab vedotin-pembrolizumab for metastatic urothelial carcinoma (mUC), yet efficacy in this setting remains undefined.
PATIENTS AND METHODS: We retrospectively reviewed an institutional database of 236 patients with mUC treated with enfortumab vedotin-pembrolizumab between October 2018 and December 2024 to identify those receiving second-line PBC. Responses were investigator-assessed. Progression-free survival (PFS) and overall survival (OS) were estimated from the start of PBC; duration of response (DOR) was estimated from the first documented response.
RESULTS: Of 62 patients treated with subsequent systemic therapy, 74% (n = 46) received PBC (carboplatin, n = 34; cisplatin, n = 12); nine patients (20%) then received maintenance avelumab. Median age was 73 years; 65% were male; 30% had upper-tract primary. Objective response rate (ORR) to first-line enfortumab vedotin-pembrolizumab was 41%. Median follow-up was 11 months [95% confidence interval (CI) 9.2-not reached (NR)]. ORR to second-line PBC was 49% (22 of 45, 95% CI 34% to 64%), including two complete responses; median DOR was 5.2 months (95% CI 3.8-NR). Median PFS was 5 months (95% CI 3.6-6.6), and median OS was 12 months (95% CI 10-17). Outcomes did not differ between cisplatin and carboplatin (P > 0.9).
CONCLUSIONS: In a real-world setting, PBC after enfortumab vedotin-pembrolizumab demonstrated meaningful activity but modest durability. These findings may inform clinical management and future trial design.
PATIENTS AND METHODS: We retrospectively reviewed an institutional database of 236 patients with mUC treated with enfortumab vedotin-pembrolizumab between October 2018 and December 2024 to identify those receiving second-line PBC. Responses were investigator-assessed. Progression-free survival (PFS) and overall survival (OS) were estimated from the start of PBC; duration of response (DOR) was estimated from the first documented response.
RESULTS: Of 62 patients treated with subsequent systemic therapy, 74% (n = 46) received PBC (carboplatin, n = 34; cisplatin, n = 12); nine patients (20%) then received maintenance avelumab. Median age was 73 years; 65% were male; 30% had upper-tract primary. Objective response rate (ORR) to first-line enfortumab vedotin-pembrolizumab was 41%. Median follow-up was 11 months [95% confidence interval (CI) 9.2-not reached (NR)]. ORR to second-line PBC was 49% (22 of 45, 95% CI 34% to 64%), including two complete responses; median DOR was 5.2 months (95% CI 3.8-NR). Median PFS was 5 months (95% CI 3.6-6.6), and median OS was 12 months (95% CI 10-17). Outcomes did not differ between cisplatin and carboplatin (P > 0.9).
CONCLUSIONS: In a real-world setting, PBC after enfortumab vedotin-pembrolizumab demonstrated meaningful activity but modest durability. These findings may inform clinical management and future trial design.